长江商报消息 ●长江商报记者 江楚雅 利德曼计划通过并购寻求新的增长曲线，推动企业转型。 近日，利德曼（300289.SZ）发布公告称，计划以17.33亿元现金收购北京先声祥瑞生物制品股份有限公 司（下称"先声祥瑞"）70%股份。 本次交易完成后，先声祥瑞将成为利德曼控股子公司，利德曼也将借此切入生物制品领域，构建"生物 制品+体外诊断"双主业模式。 业内认为，通过本次交易，上市公司的业绩将得到提升，财务状况将得到进一步改善，有利于维护上市 公司股东的利益。 标的近年业绩表现稳定 对应高溢价，交易对手方作出了明确的业绩承诺。先声祥瑞2025年、2026年、2027年扣非归母净利润分 别不低于1.66亿元（若剔除2025年mRNA平台费用1035.57万元，则为1.76亿元）、1.86亿元、2.08亿 元，三年累计扣非归母净利润不低于5.58亿元。 先声祥瑞的业务布局是此次收购的核心吸引力之一。作为拥有疫苗生产许可证的企业，其管线覆盖尚未 满足临床需求的人用创新疫苗，其中应用于脑膜炎领域的Xs03项目已提交pre-IND，另有多个创新项目 处于临床前阶段。此外，先声祥瑞在体外诊断试剂的研发、生产和销售领域也具备 ...

Core Points - The company, Lide Man (300289), reported that as of November 10, 2025, the number of shareholders reached 33,374 [1] Summary by Category - **Company Information** - Lide Man has a total of 33,374 shareholders as of the specified date [1]

Group 1 - Lidman shares increased by 5.5% on November 17, reaching 9.59 CNY per share, with a trading volume of 263 million CNY and a turnover rate of 5.36%, resulting in a total market capitalization of 5.217 billion CNY [1] - The stock price of Lidman has risen for six consecutive days, with a cumulative increase of 18.98% during this period [1] - Lidman, established on November 5, 1997, and listed on February 16, 2012, specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, with the revenue composition being 67.84% from in vitro diagnostic reagents, 14.17% from diagnostic instruments, 13.21% from other sources (such as property leasing/management), and 4.78% from biochemical raw materials [1] Group 2 - Among Lidman's top ten circulating shareholders, a fund under Yongying Fund is included, and the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 2.0113 million shares, which is 0.37% of the circulating shares [2] - The Medical Device ETF (159883) has generated a floating profit of approximately 1.0056 million CNY today and a total floating profit of 2.9164 million CNY during the six-day increase [2] - The Medical Device ETF was established on April 22, 2021, with a current scale of 4.73 billion CNY, yielding 9.67% year-to-date, ranking 3702 out of 4216 in its category, and 1.7% over the past year, ranking 3689 out of 3956, while it has incurred a loss of 46.82% since inception [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Shu Kefa, who has been in the position for 2 years and 97 days, managing a total fund size of 6.282 billion CNY [3] - During Shu Kefa's tenure, the best fund return was 103.17%, while the worst return was -30.27% [3]

Core Viewpoint - Lidman plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, aiming to enter the high-barrier bioproducts industry and transform its business model to include both bioproducts and in vitro diagnostics [1][2] Group 1: Acquisition Details - The acquisition involves cash payment to three entities: Shanghai Baijiahui Investment Management Co., Nanjing Baijiarui Enterprise Management Consulting Partnership, and Hainan Xiansheng Baijiahui Technology Development Co. [1] - After the transaction, Lidman will hold 70% of Xiansheng Xiangrui, consolidating it into its financial statements [1] Group 2: Strategic Rationale - The acquisition allows Lidman to quickly penetrate the bioproducts market, which has high barriers to entry and significant growth potential [2] - Xiansheng Xiangrui is recognized as a "little giant" enterprise in Beijing and holds a vaccine production license, with unique technologies in TB-PPD and BCG-PPD preparation [2] Group 3: Financial Performance - Xiansheng Xiangrui's projected revenues for 2023, 2024, and the first seven months of 2025 are 653 million yuan, 582 million yuan, and 228 million yuan, respectively, with net profits of 210 million yuan, 180 million yuan, and 59.68 million yuan [2] - Lidman expects the acquisition to turn its consolidated net profit positive [2] Group 4: Lidman's Current Situation - Lidman, established in 1997, focuses on in vitro diagnostic reagents and instruments but has faced revenue fluctuations due to increased competition and centralized procurement [3] - For 2024, Lidman's revenue is projected at 370 million yuan, with a net loss of 75.1 million yuan; the first three quarters of this year showed a 10.49% revenue decline [3] - As of the end of Q3, Lidman had cash reserves of 618 million yuan, and the acquisition will result in approximately 1.019 billion yuan of goodwill on its balance sheet [3]

Core Viewpoint - The acquisition of 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. by Lide Man for 1.733 billion yuan raises concerns due to high acquisition premium and the target company's declining performance, leading to potential financial risks for Lide Man [1][2][8] Group 1: Acquisition Details - Lide Man plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, representing a 162.23% premium over the assessed value of the target company [1][2] - The target company has committed to achieving non-net profit targets of 166 million yuan, 186 million yuan, and 208 million yuan for 2025, 2026, and 2027 respectively, totaling 558 million yuan over three years [1][2] - However, the target company reported a significant decline in non-net profit for the first half of 2025, at only 40 million yuan, down 65% year-on-year, raising doubts about meeting these commitments [2][3] Group 2: Financial Implications - The acquisition will generate approximately 1.019 billion yuan in goodwill, which could pose a risk of impairment if the target company’s profitability continues to decline [1][7] - Lide Man's cash reserves are only 618 million yuan, with an additional 281 million yuan in trading financial assets, totaling 899 million yuan, leaving an 800 million yuan shortfall against the acquisition price [5][7] - The acquisition is expected to significantly increase Lide Man's leverage and financial burden, as the cash payment will nearly deplete the company's total assets of 1.809 billion yuan [7][8] Group 3: Target Company Performance - The target company has shown volatile revenue and profit figures, with revenues of 639 million yuan, 653 million yuan, and 582 million yuan for 2022, 2023, and the first half of 2025 respectively, reflecting a 50.34% decline in the first half of 2025 [3][4] - The core product, TB-PPD, accounted for 95.95%, 90.47%, and 77.92% of revenue in 2023, 2024, and the first half of 2025, indicating a high dependency on a single product [3][4] - The target company's revenue from pharmaceutical promotion services in the first half of 2025 was entirely sourced from related party Jiangsu Xiansheng Pharmaceutical, raising concerns about the sustainability and authenticity of this income [4][8]

Group 1 - Duopule plans to reduce its shareholding by no more than 1%, amounting to a maximum of 619,000 shares [1] - Lideman intends to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, focusing on tuberculosis screening and diagnosis [2] - Huahuan Group is planning a change in control, leading to a temporary suspension of its stock [3] Group 2 - Dongbai Group clarifies it does not engage in duty-free business, maintaining normal operations [4][5] - Changsheng Bearing's actual controller plans to reduce holdings by up to 1.99%, equating to 5.94 million shares [6][7] - Jidian plans to invest 5.698 billion yuan in the Baicheng Phase II coal power project, a key initiative under the national "14th Five-Year Plan" [9][10] Group 3 - Baoneng New Energy reports completion of land-based works for the expansion of the Lufeng Qiaohai Bay Power Plant [11][12] - Changshu Bank proposes to appoint Lu Dingchang as the new president and chief compliance officer [13][14] - Kangqiang Electronics plans to reduce its shareholding by no more than 1%, totaling up to 3.7526 million shares [14] Group 4 - Jilin Chemical Fiber intends to reduce its holdings by up to 2%, equating to 49.1774 million shares [15][16] - CanSino's inhaled tuberculosis vaccine has commenced Phase I clinical trials in Indonesia [17][18] - ST Dongyi's stock has been suspended for review due to significant price fluctuations [19] Group 5 - ST Yatai plans to reduce its holdings by up to 1.98%, totaling 6.4 million shares [20] - Huaren Pharmaceutical intends to reduce its holdings by up to 3%, equating to 35.4663 million shares [21] - Jianglong Shipbuilding's controlling shareholder plans to reduce holdings by up to 2%, amounting to 7.5534 million shares [22] Group 6 - Borui Pharmaceutical's BGM1812 injection has received approval for clinical trials targeting overweight or obesity [23][24] - ST Zhongzhu announces the transfer of 10.38% of its shares, totaling approximately 403 million yuan [25][26] - Shenzhou Digital plans to establish an employee stock ownership plan with a maximum fundraising of 360 million yuan [27][28] Group 7 - Kaichuang Electric plans to establish a joint research center with Tsinghua University, focusing on embodied intelligence [29] - Daming City intends to acquire 19.43% of Baicaibang for 694 million yuan, specializing in communication solutions [29]

Core Viewpoint - Lideman plans to acquire 70% of Xiansheng Xiangrui Biotech for 1.733 billion yuan, marking a significant asset restructuring move [1][4][7] Group 1: Transaction Details - The acquisition price for 70% of Xiansheng Xiangrui is set at 1.733 billion yuan, with an estimated value increase of 162.23% based on the income approach [4][6][7] - The transaction involves three parties: Shanghai Baijiahui Investment Management Co., Hainan Xiansheng Baijiahui Technology Development Co., and Nanjing Baijia Rui Enterprise Management Consulting Partnership [4][5] - The deal is expected to create approximately 1.019 billion yuan in goodwill on Lideman's consolidated balance sheet post-transaction [8] Group 2: Financial Performance - Xiansheng Xiangrui's projected net profits for 2025, 2026, and 2027 are 166 million yuan, 186 million yuan, and 208 million yuan respectively, totaling a commitment of at least 560 million yuan [8] - Prior to the acquisition, Lideman's revenue for 2024 and the first seven months of 2025 were 370 million yuan and 184 million yuan, with net losses of 75.1 million yuan and 6.2 million yuan [11] - Post-acquisition, Lideman's revenue is expected to rise to 953 million yuan and 412 million yuan for the same periods, with net profits of 57.8 million yuan and 36.6 million yuan [11] Group 3: Industry Positioning - The acquisition allows Lideman to enter the high-barrier, high-potential bioproducts industry, extending its main business into internal diagnostics and innovative vaccines [9][10] - Xiansheng Xiangrui specializes in bioproducts, focusing on tuberculosis screening and diagnosis, and is one of the few companies in China with a vaccine production license [10][11] - The transaction aims to enhance Lideman's financial status and operational scale, particularly in the field of tuberculosis diagnostics [11]

标的公司去年营收净利双降。2023年度、2024年度、2025年1至7月，标的公司营业收入分别为 65,289.15万元、58,234.95万元、22,762.09万元，净利润/归属于母公司股东的净利润分别为21,042.53万 元、18,013.61万元、5,967.95万元。 中国经济网北京11月14日讯 利德曼(300289.SZ)昨晚披露的重大资产购买报告书（草案）显示，上 市公司拟向上海百家汇、海南百家汇、南京百佳瑞支付现金对价收购其所合计持有的先声祥瑞70%股 份。本次交易完成后，上市公司将直接持有先声祥瑞70%股份，取得其控股权，并将标的公司纳入合并 报表范围。 | 序号 | 交易对方 | 交易前持股比例 | 本次交易的股比 | 交易后持股比例 | | --- | --- | --- | --- | --- | | 1 | 上海百家汇 | 85.46% | 62.53% | 22.93% | | 2 | 海南白家汇 | 1.20% | 1.20% | | | 3 | 南京百佳瑞 | 8.95% | 6.26% | 2.69% | | ব | 其他股东 | 4.39% | | 4.39% | | ...

Group 1 - A-share market opened lower and fluctuated, with the medical sector showing overall activity, particularly the medical device ETF (562600) which rose by 0.22% and has seen net inflows for 12 consecutive trading days [1] - Leading stocks in the medical device sector include Reborn Medical and Lide Medical, both of which rose over 10%, while Hualan Co., Bairen Medical, and Innotec also showed strong performance [1] - Lide Medical announced a major asset purchase plan to acquire 70% of Xiansheng Xiangrui for a transaction price of 1.733 billion yuan, constituting a significant asset restructuring as the target assets exceed 50% of the listed company's total assets [1] Group 2 - The long-term positive trend in the medical device sector remains unchanged, with the medical device ETF (562600) effectively capturing structural growth opportunities in the core medical fields [2] - The ETF tracks the CSI All Index Medical Device Index, which includes 100 representative listed companies in medical devices, medical services, and medical information technology [2] - Investors can also consider alternative options such as the Huaxia CSI All Index Medical Device ETF Initiated Link A (021250) and Link C (021251) for convenient investment [2]

Monetary Policy and Financial Data - As of the end of October 2025, M2 balance reached 335.13 trillion yuan, with a year-on-year growth of 8.2% [1] - M1 balance stood at 112 trillion yuan, reflecting a year-on-year increase of 6.2% [1] - The total social financing stock was 437.72 trillion yuan, growing by 8.5% year-on-year [1] - The balance of loans to the real economy in RMB was 267.01 trillion yuan, up 6.3% year-on-year [1] Regulatory Developments - The Financial Regulatory Bureau is set to release a revised "Commercial Bank Mergers and Acquisitions Loan Management Measures" to support mergers and transformations, including for tech enterprises [4] Corporate News - Moore Threads plans to issue 70 million shares, accounting for 14.89% of total post-issue shares, with initial pricing on November 19 and subscription on November 24 [5] - SMIC reported Q3 net profit of 1.517 billion yuan, a 43.1% increase year-on-year, with revenue of 17.162 billion yuan, up 9.9% [6] - Dahua City intends to acquire a 19.43% stake in Baicai Bang for 694 million yuan, focusing on 6G and satellite internet [8] - Lide Man plans to purchase 70% of Xiansheng Xiangrui for 1.733 billion yuan, entering the bioproducts sector [10] - Higer Communication's subsidiary aims to raise up to 800 million yuan to enhance investment in unmanned and low-altitude economy [14]